Protagonist Therapeutics (PTGX) Q2 2024 Earnings
PTGX·Reported August 6, 2024·Before market open
Protagonist Therapeutics reported Q2 2024 revenue of $4.2M, missed analyst consensus of $8.0M by $3.8M. Diluted EPS came in at $-0.50.
Revenue
$4.2Mmissed by $3.8M
Consensus: $8.0MDiluted EPS
$-0.50met estimate
Consensus: $-0.50
Financial Snapshot
Trailing eight quarters through Q2 2024
Q2 2024 Earnings FAQ
Common questions about Protagonist Therapeutics's Q2 2024 earnings report.
Protagonist Therapeutics (PTGX) reported Q2 2024 earnings on August 6, 2024 before market open.
Protagonist Therapeutics reported revenue of $4.2M and diluted EPS of $-0.50 for Q2 2024.
Revenue missed the consensus estimate of $8.0M by $3.8M. EPS beat the consensus estimate of $-0.50 by $0.00.
You can read the 10-Q periodic report (0001558370-24-011095) directly on SEC EDGAR. The filing index links above go to sec.gov.